Consumer Marketing briefs

Share this article:
Two FDA studies on DTC advertising have been pushed back because of the US census, The Pink Sheet reported. FDA was gearing up for a study on the use of toll free numbers in DTC TV ads to report adverse events and another on quantitative methods for the presentation of benefit information in ads, but those studies have been pushed back to September, when the massive census effort is expected to have been completed.

Vaccines for Teens, an educational effort funded by Sanofi-Pasteur, the NBA, the WNBA and the Society for Adolescent Medicine, held events in Orlando, Detroit, Phoenix and Milwaukee featuring basketball stars counseling middle schoolers and their parents of the need for vaccinations against flu, meningitis, pertussis and HPV. Adolescents, unlike small children, often fail to get shots and are vulnerable, said a spokeswoman for the effort.

Forest Labs distributed an audio news release on fibromyalgia featuring executive director Beth Battaglino, a registered nurse. The unbranded ANR stresses the importance of early diagnosis of the disease, directing listeners to Forest makes Savella for fibromyalgia.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?